Differential effects of the two amino acid sensing systems, the GCN2 kinase and the mTOR complex 1, on primary human alloreactive CD4+ T-cells

International Journal of Molecular Medicine

Volumn 37, Issue 5, 2016, Pages 1412-1420

  Eleftheriadis, Theodoros ^a   Pissas, Georgios ^a   Antoniadi, Georgia ^a   Liakopoulos, Vassilios ^a   Tsogka, Konstantina ^a   Sounidaki, Maria ^a   Stefanidis, Ioannis ^a  

^a UNIVERSITY OF THESSALY   (Greece)

Author keywords

Apoptosis; Differentiation; General control nonderepressible 2 kinase; Mammalian target of rapamycin; Proliferation; T cell

Indexed keywords

AMINO ACID; CD4 ANTIGEN; GAMMA INTERFERON; GENERAL CONTROL NONDEREPRESSIBLE 2 KINASE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 4; LACTATE DEHYDROGENASE; LACTATE DEHYDROGENASE A; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; PHOSPHOTRANSFERASE; PROTEIN P53; RETINOIC ACID RECEPTOR GAMMA; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; CYTOKINE; EIF2AK4 PROTEIN, HUMAN; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PROTEIN SERINE THREONINE KINASE; TARGET OF RAPAMYCIN KINASE; TRANSCRIPTION FACTOR;

ADULT; ALLOIMMUNITY; APOPTOSIS; ARTICLE; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; MIXED LYMPHOCYTE REACTION; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; TH17 CELL; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; LYMPHOCYTE ACTIVATION; METABOLISM; MIDDLE AGED;

ADULT; AMINO ACIDS; BIOMARKERS; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINES; FEMALE; GENE EXPRESSION REGULATION; HUMANS; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIPROTEIN COMPLEXES; PROTEIN-SERINE-THREONINE KINASES; TOR SERINE-THREONINE KINASES; TRANSCRIPTION FACTORS;

EID: 84963546058     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2016.2547     Document Type: Article

References (49)

1. Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654, 2005.
2. Mellor AL and Munn DH: IDO expression by dendritic cells: Tolerance and tryptophan catabolism. Nat Rev Immunol 4: 762-774, 2004.
3. Dong J, Qiu H, Garcia-Barrio M, Anderson J and Hinnebusch AG: Uncharged tRNA activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. Mol Cell 6: 269-279, 2000.
4. Gallinetti J, Harputlugil E and Mitchell JR: Amino acid sensing in dietary-restriction-mediated longevity: Roles of signal-transducing kinases GCN2 and TOR. Biochem J 449: 1-10, 2013.
5. Sancak Y, Peterson TR, Shaul YD, Lindquist RA, Thoreen CC, Bar-Peled L and Sabatini DM: The Rag GTPases bind raptor and mediate amino acid signaling to mTORC1. Science 320: 1496-1501, 2008.
6. Kim E, Goraksha-Hicks P, Li L, Neufeld TP and Guan KL: Regulation of TORC1 by Rag GTPases in nutrient response. Nat Cell Biol 10: 935-945, 2008.
7. + T cells. Immunology 146: 292-300, 2015.
8. Kilberg MS, Shan J and Su N: ATF4-dependent transcription mediates signaling of amino acid limitation. Trends Endocrinol Metab 20: 436-443, 2009.
9. Castilho BA, Shanmugam R, Silva RC, Ramesh R, Himme BM and Sattlegger E: Keeping the eIF2 alpha kinase Gcn2 in check. Biochim Biophys Acta 1843: 1948-1968, 2014.
10. Laplante M and Sabatini DM: mTOR signaling at a glance. J Cell Sci 122: 3589-3594, 2009.
11. Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nat Rev Mol Cell Biol 10: 307-318, 2009.
12. Shihab F, Christians U, Smith L, Wellen JR and Kaplan B: Focus on mTOR inhibitors and tacrolimus in renal transplantation: Pharmacokinetics, exposure-response relationships, and clinical outcomes. Transpl Immunol 31: 22-32, 2014.
13. Eleftheriadis T, Pissas G, Antoniadi G, Spanoulis A, Liakopoulos V and Stefanidis I: Indoleamine 2, 3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2, 3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation. Int Immunol 26: 673-684, 2014.
14. Munn DH, Sharma MD, Baban B, Harding HP, Zhang Y, Ron D and Mellor AL: GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2, 3-diox-ygenase. Immunity 22: 633-642, 2005.
15. Alexander AM, Crawford M, Bertera S, Rudert WA, Takikawa O, Robbins PD and Trucco M: Indoleamine 2, 3-dioxygenase expression in transplanted NOD Islets prolongs graft survival after adoptive transfer of diabetogenic splenocytes. Diabetes 51: 356-365, 2002.
16. Beutelspacher SC, Pillai R, Watson M P, Tan PH, Tsang J, McClure MO, George AJ and Larkin DF: Function of indoleamine 2, 3-dioxygenase in corneal allograft rejection and prolongation of allograft survival by over-expression. Eur J Immunol 36: 690-700, 2006.
17. Li Y, Tredget EE, Ghaffari A, Lin X, Kilani RT and Ghahary A: Local expression of indoleamine 2, 3-dioxygenase protects engraftment of xenogeneic skin substitute. J Invest Dermatol 126: 128-136, 2006.
18. Munn DH, Zhou M, Attwood JT, Bondarev I, Conway SJ, Marshall B, Brown C and Mellor AL: Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281: 1191-1193, 1998.
19. Sato T, Deiwick A, Raddatz G, Koyama K and Schlitt HJ: Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): Influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 115: 301-308, 1999.
20. Lowe G and Tansley G: An investigation of the mechanism of activation of tryptophan by tryptophanyl-tRNA synthetase from beef pancreas. Eur J Biochem 138: 597-602, 1984.
21. Fadeel B and Orrenius S: Apoptosis: A basic biological phenomenon with wide-ranging implications in human disease. J Intern Med 258: 479-517, 2005.
22. Pines M and Spector I: Halofuginone-the multifaceted molecule. Molecules 20: 573-594, 2015.
23. Chu TL, Guan Q, Nguan CY and Du C: Halofuginone suppresses T cell proliferation by blocking proline uptake and inducing cell apoptosis. Int Immunopharmacol 16: 414-423, 2013.
24. Forouzandeh F, Jalili RB, Germain M, Duronio V and Ghahary A: Skin cells, but not T cells, are resistant to indoleamine 2, 3-dioxy-genase IDO) expressed by allogeneic fbroblasts. Wound Repair Regen 16: 379-387, 2008.
25. Habibi D, Jalili RB, Forouzandeh F, Ong CJ and Ghahary A: High expression of IMPACT protein promotes resistance to indoleamine 2, 3-dioxygenase-induced cell death. J Cell Physiol 225: 196-205, 2010.
26. Weichhart T, Costantino G, Poglitsch M, Rosner M, Zeyda M, Stuhlmeier KM, Kolbe T, Stulnig TM, Hörl WH, Hengstschläger M, et al: The TSC-mTOR signaling pathway regulates the innate inflammatory response. Immunity 29: 565-577, 2008.
27. Choi SJ, You HS and Chung SY: Rapamycin-induced cytotoxic signal transduction pathway. Transplant Proc 40: 2737-2739, 2008.
28. Brady CA and Attardi LD: p53 at a glance. J Cell Sci 123: 2527-2532, 2010.
29. Metcalfe SM, Canman CE, Milner J, Morris RE, Goldman S and Kastan MB: Rapamycin and p53 act on different pathways to induce G1 arrest in mammalian cells. Oncogene 15: 1635-1642, 1997.
30. Miyake N, Chikumi H, Takata M, Nakamoto M, Igishi T and Shimizu E: Rapamycin induces p53-independent apoptosis through the mitochondrial pathway in non-small cell lung cancer cells. Oncol Rep 28: 848-854, 2012.
31. Raphael I, Nalawade S, Eagar TN and Forsthuber TG: T cell subsets and their signature cytokines in autoimmune and infam-matory diseases. Cytokine 74: 5-17, 2015.
32. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, Orabona C, Bianchi R, Belladonna ML, Volpi C, et al: The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 176: 6752-6761, 2006.
33. Ito H, Ando T, Ando K, Ishikawa T, Saito K, Moriwaki H and Seishima M: Induction of hepatitis B virus surface antigen-specifc cytotoxic T lymphocytes can be up-regulated by the inhibition of indoleamine 2, 3-dioxygenase activity. Immunology 142: 614-623, 2014.
34. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ and Bradfield CA: An interaction between kynurenine and the aryl hydrocarbon receptor can generate regulatory T cells. J Immunol 185: 3190-3198, 2010.
35. Delgoffe GM, Kole TP, Zheng Y, Zarek PE, Matthews KL, Xiao B, Worley PF, Kozma SC and Powell JD: The mTOR kinase differentially regulates effector and regulatory T cell lineage commitment. Immunity 30: 832-844, 2009.
36. Pollizzi KN and Powell JD: Regulation of T cells by mTOR: The known knowns and the known unknowns. Trends Immunol 36: 13-20, 2015.
37. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, Magnuson MA and Boothby M: Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 32: 743-753, 2010.
38. Delgoffe GM, Pollizzi KN, Waickman AT, Heikamp E, Meyers DJ, Horton MR, Xiao B, Worley PF and Powell JD: The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat Immunol 12: 295-303, 2011.
39. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, Bagley AF, Markhard AL and Sabatini DM: Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168, 2006.
40. Askar M: T helper subsets and regulatory T cells: Rethinking the paradigm in the clinical context of solid organ transplantation. Int J Immunogenet 41: 185-194, 2014.
41. Pan F, Barbi J and Pardoll DM: Hypoxia-inducible factor 1: A link between metabolism and T cell differentiation and a potential therapeutic target. Oncoimmunology 1: 510-515, 2012.
42. Dang EV, Barbi J, Yang HY, Jinasena D, Yu H, Zheng Y, Bordman Z, Fu J, Kim Y, Yen HR, et al: Control of T(H)17/T(reg) balance by hypoxia-inducible factor 1. Cell 146: 772-784, 2011.
43. Hudson CC, Liu M, Chiang GG, Otterness DM, Loomis DC, Kaper F, Giaccia AJ and Abraham RT: Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol 22: 7004-7014, 2002.
44. Sutton TA, Wilkinson J, Mang HE, Knipe NL, Plotkin Z, Hosein M, Zak K, Wittenborn J and Dagher PC: p53 regulates renal expression of HIF-1{alpha} and pVHL under physiological conditions and after ischemia-reperfusion injury. Am J Physiol Renal Physiol 295: F1666-F1677, 2008.
45. Nieminen AL, Qanungo S, Schneider EA, Jiang BH and Agani FH: Mdm2 and HIF-1alpha interaction in tumor cells during hypoxia. J Cell Physiol 204: 364-369, 2005.
46. Kaluz S, Kaluzová M and Stanbridge EJ: Does inhibition of degradation of hypoxia-inducible factor (HIF) alpha always lead to activation of HIF? Lessons learnt from the effect of proteasomal inhibition on HIF activity. J Cell Biochem 104: 536-544, 2008.
47. Schmid T, Zhou J, Köhl R and Brüne B: p300 relieves p53-evoked transcriptional repression of hypoxia-inducible factor-1 (HIF-1). Biochem J 380: 289-295, 2004.
48. François M, Romieu-Mourez R, Li M and Galipeau J: Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and bystander M2 macrophage differentiation. Mol Ther 20: 187-195, 2012.
49. Mercalli A, Calavita I, Dugnani E, Citro A, Cantarelli E, Nano R, Melzi R, Maff P, Secchi A, Sordi V, et al: Rapamycin unbalances the polarization of human macrophages to M1. Immunology 140: 179-190, 2013.